Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis

Withdrawn before enrolling · Phase 4

Conditions studied: Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis

In brief

This proposal will test the hypothesis that Orencia affects apoptosis and apoptosis related genes/biomarkers in vivo in rheumatoid arthritis (RA) patients.

Key facts

Study ID

NCT01717846

Run by

University of California, Los Angeles

People needed

0

Starts

2012-12-01

Expected to finish

2014-11-01

Last updated by the study team

2016-05-11

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Over age 18
• Meeting ACR Criteria 1987 for RA diagnosis
• Naïve to treatment with abatacept
• Must be able to understand information in the Informed Consent

You may not qualify if…

• Pregnancy or breast feeding
• Previous exposure to abatacept.
• History of a concomitant autoimmune disease (eg. SLE, PsA etc.)
• Patients with history of cancer

Where it is running

• Univerity of California at Los Angeles — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.